Asciminib for relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Asciminib, an allosteric inhibitor of BCR::ABL1, is an effective salvage therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. In a study of 41 patients, 30 out of 36 evaluable patients achieved a composite complete response. Its efficacy, particularly event-free survival, was improved when administered in combination. New mutations of resistance may occur, warranting further investigation.